Patiromer for the treatment of hyperkalemia
- 2 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (6), 563-570
- https://doi.org/10.1080/17512433.2020.1774363
Abstract
Hyperkalemia is a chronic and life-threatening electrolyte disorder that affects millions of patients around the world with decreased kidney function, hypertension, and heart failure. Recently newer oral potassium-binding agents have been approved for clinical use, as an alternative to the decades long use of sodium polystyrene sulfonate. This review will focus on the patiromer and its use in reducing hyperkalemia. Pubmed was used to search from 1960 to 2020 on free subject terms: Hyperkalemia, Potassium, Patiromer, Veltassa, Kayexalate, Sodium polystyrene sulfonate, and Sodium Zirconium cyclosilicate. The authors have reviewed the literature and summarized the most salient elements in regards to patiromer. Patiromer has been available on the US market since 2015 when approved by the FDA for clinical use. Clinical trials monitoring patient use for up to 1 year have shown clinically meaningful potassium reductions, sustained normokalemia, high tolerability, and without major serious adverse events. Patiromer is available to all patients experiencing hyperkalemia, no matter the disease state leading to the condition. It is likely this newer oral potassium-binding agent will help change how patients with hyperkalemia are treated in regards to sudden and chronic medical conditions.Keywords
This publication has 44 references indexed in Scilit:
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS InhibitorsThe New England Journal of Medicine, 2015
- Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With HyperkalemiaJAMA, 2014
- Homeostasis, the Milieu Intérieur, and the Wisdom of the NephronClinical Journal of the American Society of Nephrology, 2014
- IN VITRO ION EXCHANGE CAPACITY AND SELECTIVITY OF ZS-9, A NOVEL, SELECTIVE CATION TRAP FOR THE TREATMENT OF HYPERKALEMIAAmerican Journal of Kidney Diseases, 2014
- The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemiaJournal of Hospital Medicine, 2011
- Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 2011
- A Physiologic-Based Approach to the Evaluation of a Patient With HyperkalemiaAmerican Journal of Kidney Diseases, 2010
- Intestinal Necrosis due to Sodium Polystyrene Sulfonate (Kayexalate) in SorbitolSouthern Medical Journal, 2009
- Ionic constituents and osmolality of gastric and small-intestinal fluids after eatingDigestive Diseases and Sciences, 1966
- Treatment of the Oliguric Patient with a New Sodium-Exchange Resin and SorbitolThe New England Journal of Medicine, 1961